Published in Am J Med on December 01, 1980
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother (1995) 2.61
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
Rapid identification of antibiotic-resistant corynebacteria with the API 20S system. J Clin Microbiol (1984) 2.01
Genomic diversity among Corynebacterium jeikeium strains and comparison with biochemical characteristics and antimicrobial susceptibilities. J Clin Microbiol (1994) 1.64
In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 1.56
Native valve endocarditis caused by an organism resembling Corynebacterium striatum. J Clin Microbiol (1990) 1.51
Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol (1984) 1.33
Corynebacterium endocarditis species-specific risk factors and outcomes. BMC Infect Dis (2007) 1.24
Isolation of Corynebacterium group JK from clinical specimens with a semiselective medium. J Clin Microbiol (1984) 1.19
Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother (1989) 1.19
Corynebacterium jeikeium endocarditis: a systematic overview spanning four decades. Eur J Clin Microbiol Infect Dis (2006) 1.17
Use of selective broth enrichment to determine the prevalence of multiply resistant JK corynebacteria on skin. J Clin Microbiol (1982) 1.14
Nosocomial endocarditis caused by Corynebacterium amycolatum and other nondiphtheriae corynebacteria. Emerg Infect Dis (2002) 1.12
Biochemical and cultural characteristics of "JK" coryneforms. J Clin Pathol (1986) 1.06
Prosthetic valve endocarditis caused by Corynebacterium afermentans subsp. lipophilum (CDC coryneform group ANF-1). J Clin Microbiol (1995) 1.01
Outbreak of JK diphtheroid infections associated with environmental contamination. J Clin Microbiol (1984) 1.01
The lowly diphtheriod: nondiphtheria corynebacterial infections in humans. West J Med (1982) 0.92
Antimicrobial susceptibilities of a Corynebacterium CDC group I1 strain isolated from a patient with endocarditis. Antimicrob Agents Chemother (1992) 0.84
Group JK corynebacterium peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. J Clin Microbiol (1983) 0.80
In vitro activity of SK&F 104662, a new glycopeptide antibiotic. Antimicrob Agents Chemother (1989) 0.78
Prosthetic valve endocarditis caused by Corynebacterium diphtheriae in a patient with pemphigus vulgaris. J Clin Microbiol (1987) 0.78
Synergistic activity between vancomycin or teicoplanin and gentamicin or tobramycin against pathogenic diphtheroids. Antimicrob Agents Chemother (1988) 0.75
Pacemaker associated infection due to a corynebacterium species. Tex Heart Inst J (1985) 0.75
An unusual etiological agent of implantable cardioverter device endocarditis: Corynebacterium mucifaciens. Indian Heart J (2016) 0.75
Splenic abscess caused by Propionibacterium acnes. Yale J Biol Med (1982) 0.75
Corynebacterium CDC Group G Native and Prosthetic Valve Endocarditis. Infect Dis Rep (2015) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis (1983) 6.01
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J Clin Microbiol (1991) 5.86
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest (1983) 5.59
Infections in patients with diabetes mellitus. N Engl J Med (1999) 5.39
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci U S A (2001) 4.69
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis (1993) 4.28
Comparison of ribotyping and pulsed-field gel electrophoresis for subspecies differentiation of strains of Enterococcus faecalis. J Clin Microbiol (1993) 4.14
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Assessment and management of foot disease in patients with diabetes. N Engl J Med (1994) 3.83
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother (1996) 3.48
Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother (1986) 3.33
Prosthetic valve endocarditis. Analysis of 38 cases. Circulation (1973) 3.29
Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J Infect Dis (1998) 3.28
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect Immun (2000) 3.15
Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med (1999) 3.08
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides. Antimicrob Agents Chemother (1983) 2.88
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J Bacteriol (2001) 2.67
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1990) 2.61
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med (1999) 2.56
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis (2001) 2.53
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis (1996) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Incidence of hemolysin, gelatinase, and aggregation substance among enterococci isolated from patients with endocarditis and other infections and from feces of hospitalized and community-based persons. J Infect Dis (1995) 2.37
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Diagnosis and therapy of Kawasaki disease in children. Circulation (1993) 2.32
In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J Clin Invest (1986) 2.31
Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis (1994) 2.29
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med (1982) 2.27
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Polymerase chain reaction for diagnosis of enterohemorrhagic Escherichia coli infection and hemolytic-uremic syndrome. J Clin Microbiol (1992) 2.24
Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains. J Clin Microbiol (1994) 2.23
In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol Med Microbiol (1998) 2.21
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis (1987) 2.17
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA (1995) 2.09
Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect Immun (2000) 2.09
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Molecular epidemiology of beta-lactamase-producing enterococci. Antimicrob Agents Chemother (1990) 2.06
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
Characterization of the gentamicin resistance transposon Tn5281 from Enterococcus faecalis and comparison to staphylococcal transposons Tn4001 and Tn4031. Antimicrob Agents Chemother (1991) 1.97
Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis (1998) 1.97
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect (2010) 1.94
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Limitations of using the plasmid pattern as an epidemiological tool for clinical isolates of Shigella sonnei. J Infect Dis (1987) 1.92
Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun (2000) 1.91
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother (1974) 1.86
A cluster of genes involved in polysaccharide biosynthesis from Enterococcus faecalis OG1RF. Infect Immun (1998) 1.86